Innocan to roll back shares one for 65

Ms. Iris Bincovich reports INNOCAN PHARMA ANNOUNCES DETAILS OF PROPOSED SHARE CONSOLIDATION Further to the press release dated July 23, 2025, Innocan Pharma Corp. will consolidate all of its issued and outstanding common shares on the basis of one postconsolidation common share for every 65 preconsolidation common shares. The share consolidation represents another step toward the completion of a proposed public offering of units in the United States as set out in its registration statement on Form F-1 that has been publicly filed with the U.S. Securities and Exchange Commission and the listing of the common shares on Nasdaq Capital Market. Each unit will be composed of one common share of the company and one common share purchase warrant of the company. Each warrant will entitle the holder thereof to purchase one common share at an exercise price and term in the context of the market. Innocan has applied to list its common shares and warrants on Nasdaq Capital Market under the symbols INNP and INNPW, respectively. ThinkEquity LLC is acting as representative underwriter in the offering. This proposed offering will be made only by means of a prospectus. Upon availability, copies of the preliminary prospectus related to the proposed offering may be obtained from ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004. The final prospectus will be filed with the SEC and will be available on the SEC's website. A registration statement relating to this offering has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication to the market shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About the share consolidation, Iris Bincovich, chief executive officer of Innocan, stated, "We are pleased to take this step as part of our plan to complete a U.S. public offering and Nasdaq listing." Share consolidation details At the company's annual and special meeting of shareholders held on June 26, 2025, the company's shareholders approved a share consolidation on the basis of one postconsolidation common share for up to every 100 preconsolidation common shares and authorized the board of directors of the company to select a lesser consolidation ratio at its sole discretion. The board of directors has since fixed the consolidation ratio on a one-for-65 basis. It is expected that the common shares will commence trading on a postshare consolidation basis on the Canadian Securities Exchange on or about Sept. 5, 2025, subject to the approval of the CSE. Assuming the share consolidation is completed, the existing 292,420,157 common shares will be reduced to approximately 4,498,772 common shares, subject to adjustments for rounding purposes. No fractional shares will be issued. Any fractional interest in common shares that is less than 0.5 of a common share resulting from the share consolidation will be rounded down to the nearest whole common share, and any fractional interest in common shares that is 0.5 or greater of a common share will be rounded up to the nearest whole common share. Upon completion of the share consolidation, a letter of transmittal will be sent by mail to registered shareholders advising that the share consolidation has taken effect. The letter of transmittal will contain instructions on how registered shareholders can exchange their share certificates or direct registration system statements evidencing their preconsolidation common shares for new share certificates or new DRS statements representing the number of postconsolidation common shares to which they are entitled. Beneficial shareholders holding their common shares through an intermediary may be subject to different procedures for obtaining their postconsolidation shares. If you have questions in this regard, you are encouraged to contact your intermediary. The company does not intend to change its name or seek a new stock trading symbol in connection with the share consolidation. About Innocan Pharma Corp. Innocan is an innovator in the pharmaceutical and wellness sectors. In the pharmaceutical sector, Innocan developed a cannabidiol-loaded liposome drug delivery platform with exact dosing and prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan focuses on advanced, targeted on-line sales through its BI Sky Global Ltd. subsidiary. We seek Safe Harbor.